The other 2nd line agents are pretty clearly somewhat superior efficacy-wise to Gleevec based on head-to-head trials. All that Gleevec has going for it is much more long-term data and greater familiarity by doctors. Nevertheless, once Gleevec goes generic, I expect most insurers to require Gleevec be tried first in some sort of step-therapy approach.
The point here is that Gleevec performs remarkably well in general - the other drugs' improvements over Gleevec are really very much second-order effects.
That said, pona will do very well indeed if it becomes the 2nd-line drug of choice and the 1st-line drug for Sokal high-risk patients.
Note Gleevec actually has some Orange book formulation patents that go beyond 2015 - I think they go to 2019. Remains to be seen if they hold up or not - perhaps they get a settlement that delays generics until something like 2016/2017. So that's enough time for pona to get a decent foothold first.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.